Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 19/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1995372 | 0.80 | KIF11 (0.56) | KIF11 | |
| SCHEMBL34230 | 0.79 | KIF11 (0.50) | KIF11SIRT2 | |
| SCHEMBL5536601 | 0.77 | HDAC1 (0.49) | — | |
| SCHEMBL5544649 | 0.77 | HDAC1 (0.49) | — | |
| SCHEMBL8447103 | 0.76 | KIF11 (0.44) | KIF11 | |
| SCHEMBL8447105 | 0.76 | KIF11 (0.44) | KIF11 | |
| SCHEMBL8504226 | 0.75 | KIF11 (0.50) | KIF11 | |
| SCHEMBL98808 | 0.75 | KIF11 (0.53) | KIF11SIRT2 | |
| SCHEMBL5543716 | 0.75 | ALDH1A1 (0.50) | — | |
| SCHEMBL9889271 | 0.74 | KIF11 (0.45) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9872864-B2 | Sustained release composition of prostacyclin | ASCENDIS PHARMA A/S (DK) | 2018-01-23 | — | — | US | disclosed |
| US-9561287-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2017-02-07 | — | — | US | disclosed |
| US-9457066-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9138462-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-20150258207-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-9133276-B2 | Prodrugs comprising an exendin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | ASCENDIS PHARMA A/S (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140296150-A1 | Carrier-Linked Treprostinil Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296150-A1 | Carrier-Linked Treprostinil Prodrugs | PAH, TK1, SLC16A1 | KIF11 1524/4885SIRT2 253/4885 |
| US-20150258207-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | KIF11 2883/4885SIRT2 444/4885 |
| US-20120156259-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | KIF11 3432/4885SIRT2 1578/4885 |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | KIF11 2883/4885SIRT2 444/4885 |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | IAPP, INSR, GPR119 | KIF11 3201/4885SIRT2 1019/4885 |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | PTGIR, PTGIS, PTGS1 | KIF11 3742/4885SIRT2 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.